

Violation Tracker Industry Summary Page

Industry: pharmaceuticals
Penalty Total since 2000: \$126,444,335,963
Number of Records: 1,323
Note: The totals include only those entries matched to a parent company. The industry designation is the primary one for the parent's operations overall. The totals are adjusted to account for the fact that each parent's entries may include both agency records and settlement announcements for the same case; or else a penalty covering multiple locations may be listed in the individual records for each of the facilities. They are also adjusted to reflect cases in which federal and state or local agencies cooperated and issued separate announcements of the outcome. Duplicate or overlapping penalty amounts are marked with an asterisk in the individual records list below.

TOP 10 CURRENT PARENT COMPANIES	TOTAL PENALTY \$	NUMBER OF RECORDS
Johnson & Johnson	\$25,117,910,922	81
GSK plc	\$11,777,303,406	52
Pfizer	\$11,261,560,400	107
Merck	\$10,710,400,031	89
Teva Pharmaceutical Industries	\$10,695,276,796	98
Purdue Pharma	\$10,178,372,787	12
AbbVie	\$7,565,081,404	85
Endo International	\$4,847,990,667	31
Takeda Pharmaceutical	\$3,987,516,447	32
Eli Lilly	\$3,014,987,327	27

Individual Penalty Records:

Click on the company or penalty amount for more information on each case. Click on the parent name to reach the summary page for that parent company.

Download results as [CSV](#) or [XML](#) or  Save your search ([Click here](#) for information on download subscriptions)

COMPANY	CURRENT PARENT	PRIMARY OFFENSE TYPE	YEAR	AGENCY	PENALTY AMOUNT
Johnson & Johnson	Johnson & Johnson	product safety violation	2023	private lawsuit-federal	\$8,900,000,000
Purdue Pharma LP	Purdue Pharma	fraud	2020	DOJ_CIVIL	\$8,344,000,000
Johnson & Johnson	Johnson & Johnson	off-label or unapproved promotion of medical products	2021	MULTI-AG	\$5,000,000,000
Merck & Co.	Merck	drug or medical equipment safety violation	2007	private lawsuit-federal	\$4,850,000,000
Teva Pharmaceuticals	Teva Pharmaceutical Industries	off-label or unapproved promotion of medical products	2022	MULTI-AG	\$4,250,000,000
American Home Products	Pfizer	drug or medical equipment safety violation	2002	private lawsuit-federal	\$3,750,000,000
GlaxoSmithKline Holdings (Americas)	GSK plc	tax violations	2006	IRS	\$3,400,000,000
GlaxoSmithKline LLC	GSK plc	off-label or unapproved promotion of medical products	2012	FDA	\$3,000,000,000
Johnson & Johnson	Johnson & Johnson	product safety violation	2021	private lawsuit-federal	\$2,500,000,000
DePuy Orthopaedics, Inc.	Johnson & Johnson	drug or medical equipment safety violation	2013	private lawsuit-federal	\$2,475,000,000
Takeda Pharmaceutical Co. Ltd.	Takeda Pharmaceutical	drug or medical equipment	2015	private lawsuit-federal	\$2,400,000,000

COMPANY	CURRENT PARENT	PRIMARY OFFENSE TYPE	YEAR	AGENCY	PENALTY AMOUNT
		safety violation			
Allergan	AbbVie	off-label or unapproved promotion of medical products	2022	MULTI-AG	\$2,370,000,000
Pfizer Inc.	Pfizer	off-label or unapproved promotion of medical products	2009	FDA	\$2,300,000,000
Merck & Co., Inc.	Merck	tax violations	2007	IRS	\$2,300,000,000
Johnson & Johnson	Johnson & Johnson	off-label or unapproved promotion of medical products	2013	FDA	\$2,200,000,000
GSK PLC	GSK plc	drug or medical equipment safety violation	2024	private lawsuit-state	\$2,200,000,000
Mallinckrodt	Mallinckrodt	Controlled Substances Act violation	2020	MULTI-AG	\$1,600,000,000
Endo Health Solutions Inc.	Endo International	drug or medical equipment safety violation	2024	DOJ_CIVIL	\$1,536,000,000
Abbott Laboratories Inc.	AbbVie	off-label or unapproved promotion of medical products	2012	FDA	\$1,500,000,000
Eli Lilly and Company	Eli Lilly	off-label or unapproved promotion of medical products	2009	FDA	\$1,415,000,000
Cephalon, Inc.	Teva Pharmaceutical Industries	price-fixing or anti-competitive practices	2015	FTC	\$1,200,000,000
Merck, Sharp & Dohme	Merck	off-label or unapproved promotion	2011	FDA	\$950,000,000

COMPANY	CURRENT PARENT	PRIMARY OFFENSE TYPE	YEAR	AGENCY	PENALTY AMOUNT
		of medical products			
Biogen Inc.	Biogen	False Claims Act and related	2022	DOJ_CIVIL	\$ 900,000,000
Purdue Pharma LP	Purdue Pharma	off-label or unapproved promotion of medical products	2025	MULTI-AG	\$ 900,000,000
TAP Pharmaceutical Products Inc.	Takeda Pharmaceutical	False Claims Act and related	2001	DOJ_CIVIL	\$ 875,000,000
Endo International PLC	Endo International	drug or medical equipment safety violation	2014	private lawsuit-federal	\$ 830,000,000
Pfizer Inc.	Pfizer	False Claims Act and related	2016	DOJ_CIVIL	\$ 784,600,000
Endo International PLC	Endo International	drug or medical equipment safety violation	2017	private lawsuit-federal	\$ 775,000,000
GlaxoSmithKline	GSK plc	drug or medical equipment safety violation	2010	private lawsuit-federal	\$ 770,000,000
Amgen Inc.	Amgen	off-label or unapproved promotion of medical products	2012	FDA	\$ 762,000,000
SB Pharmco Puerto Rico Inc.	GSK plc	drug or medical equipment safety violation	2010	FDA	\$ 750,000,000
Pfizer	Pfizer	drug or medical equipment safety violation	2004	private lawsuit-federal	\$ 750,000,000
Forest Laboratories LLC	AbbVie	price-fixing or anti-competitive practices	2020	private lawsuit-federal	\$ 750,000,000

COMPANY	CURRENT PARENT	PRIMARY OFFENSE TYPE	YEAR	AGENCY	PENALTY AMOUNT
Pfizer	Pfizer	drug or medical equipment safety violation	2008	private lawsuit-federal	\$ 745,000,000
Serono, S.A.	Merck KGaA (EMD)	off-label or unapproved promotion of medical products	2005	FDA	\$ 704,000,000
Johnson & Johnson	Johnson & Johnson	consumer protection violation	2024	MULTI-AG	\$ 700,000,000
Eli Lilly and Company	Eli Lilly	drug or medical equipment safety violation	2005	private lawsuit-federal	\$ 690,000,000
Merck & Company	Merck	False Claims Act and related	2008	DOJ_CIVIL	\$ 650,000,000
Boehringer Ingelheim International	Boehringer Ingelheim	drug or medical equipment safety violation	2014	private lawsuit-federal	\$ 650,000,000
Novartis Pharmaceuticals Corporation	Novartis	False Claims Act and related	2020	DOJ_CIVIL	(*) \$ 642,000,000
Amgen Inc.	Amgen	off-label or unapproved promotion of medical products	2012	MULTI-AG	(*) \$ 612,000,000
Allergan Inc.	AbbVie	off-label or unapproved promotion of medical products	2010	FDA	\$ 600,000,000
Abbott Laboratories and CG Nutritionals	Abbott Laboratories	False Claims Act and related	2003	DOJ_CIVIL	\$ 600,000,000
Purdue Frederick Company Inc.	Purdue Pharma	False Claims Act and related	2007	USAO	\$ 600,000,000
Indivior Solutions	Indivior PLC	False Claims Act and related	2020	DOJ_CIVIL	\$ 589,000,000
Johnson & Johnson	Johnson & Johnson	off-label or unapproved	2013	MULTI-AG	(*) \$ 541,000,000

COMPANY	CURRENT PARENT	PRIMARY OFFENSE TYPE	YEAR	AGENCY	PENALTY AMOUNT
		promotion of medical products			
AstraZeneca LP	AstraZeneca	off-label or unapproved promotion of medical products	2010	FDA	\$ 520,000,000
Bristol-Myers Squibb Company	Bristol-Myers Squibb	off-label or unapproved promotion of medical products	2007	DOJ_CIVIL	\$ 515,000,000
Teva Pharmaceuticals USA Inc.	Teva Pharmaceutical Industries	price-fixing or anti-competitive practices	2015	private lawsuit-federal	\$ 512,000,000
Ranbaxy USA Inc.	Sun Pharmaceuticals	drug or medical equipment safety violation	2013	FDA	\$ 500,000,000
Schering-Plough Corporation	Merck	drug or medical equipment safety violation	2002	DOJ_CIVIL	\$ 500,000,000
Eli Lilly and Company	Eli Lilly	drug or medical equipment safety violation	2007	private lawsuit-federal	\$ 500,000,000
Wyeth Pharmaceuticals Inc.	Pfizer	off-label or unapproved promotion of medical products	2013	FDA	\$ 490,900,000
Ranbaxy, Inc.	Sun Pharmaceuticals	price-fixing or anti-competitive practices	2022	private lawsuit-federal	\$ 485,000,000
GlaxoSmithKline	GSK plc	off-label or unapproved promotion of medical products	2012	MULTI-AG	(*) \$ 477,792,391
Mylan Inc.	Viatris	False Claims Act and related	2017	DOJ_CIVIL	\$ 465,000,000
Mylan Inc.	Viatris	False Claims Act	2017	MULTI-AG	(*) \$ 465,000,000

COMPANY	CURRENT PARENT	PRIMARY OFFENSE TYPE	YEAR	AGENCY	PENALTY AMOUNT
		and related			
Endo Health Solutions Inc.	Endo International	drug or medical equipment safety violation	2024	DOJ_CIVIL	\$ 464,900,000
Bristol-Myers Squibb Company et al.	Bristol-Myers Squibb	product safety violation	2024	HI-AG	\$ 458,006,000
Sanofi	Sanofi	product safety violation	2024	HI-AG	\$ 458,006,000
Endo International plc	Endo International	off-label or unapproved promotion of medical products	2022	MULTI-AG	\$ 450,000,000
Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc.	Teva Pharmaceutical Industries	False Claims Act and related	2024	DOJ_CIVIL	\$ 450,000,000
Schering-Plough Corporation	Merck	off-label or unapproved promotion of medical products	2006	USAO	\$ 435,000,000
Warner-Lambert	Pfizer	off-label or unapproved promotion of medical products	2004	FDA	\$ 430,000,000
Cephalon Inc	Teva Pharmaceutical Industries	off-label or unapproved promotion of medical products	2008	FDA	\$ 425,000,000
AstraZeneca	AstraZeneca	product safety violation	2023	private lawsuit-federal	\$ 425,000,000
Novartis Pharmaceuticals Corporation	Novartis	off-label or unapproved promotion of medical products	2010	FDA	\$ 422,500,000
Janssen Pharmaceuticals, Inc.	Johnson & Johnson	off-label or unapproved promotion of medical products	2013	USAO	\$ 410,000,000

COMPANY	CURRENT PARENT	PRIMARY OFFENSE TYPE	YEAR	AGENCY	PENALTY AMOUNT
Novartis Pharmaceuticals	Novartis	kickbacks and bribery	2015	USAO	\$ 390,000,000
Janssen Pharmaceuticals	Johnson & Johnson	drug or medical equipment safety violation	2019	private lawsuit-federal	\$ 387,500,000
Indivior Inc.	Indivior PLC	price-fixing or anti-competitive practices	2024	private lawsuit-federal	\$ 385,000,000
Wyeth Pharmaceuticals, Inc.	Pfizer	False Claims Act and related	2016	MULTI-AG	(*) \$ 371,351,180
Eli Lilly and Company	Eli Lilly	off-label or unapproved promotion of medical products	2009	MULTI-AG	(*) \$ 361,828,456
Actelion Pharmaceuticals US, Inc.	Johnson & Johnson	False Claims Act and related	2018	DOJ_CIVIL	\$ 360,000,000
AstraZeneca Pharmaceuticals LP	AstraZeneca	False Claims Act and related	2003	DOJ_CIVIL	\$ 354,900,000
Shire Pharmaceuticals LLC	Takeda Pharmaceutical	False Claims Act and related	2017	DOJ_CIVIL	\$ 350,000,000
Bristol-Myers Squibb	Bristol-Myers Squibb	off-label or unapproved promotion of medical products	2025	HI-AG	\$ 350,000,000
Sanofi	Sanofi	off-label or unapproved promotion of medical products	2025	HI-AG	\$ 350,000,000
Schering-Plough Corporation	Merck	kickbacks and bribery	2004	DOJ_CIVIL	\$ 345,000,000
Pfizer Inc.	Pfizer	price-fixing or anti-competitive practices	2021	private lawsuit-federal	\$ 345,000,000
Abbott Laboratories	AbbVie	off-label or unapproved promotion of medical products	2012	MULTI-AG	(*) \$ 339,148,643

COMPANY	CURRENT PARENT	PRIMARY OFFENSE TYPE	YEAR	AGENCY	PENALTY AMOUNT
Mylan Inc.	Viatris	off-label or unapproved promotion of medical products	2025	MULTI-AG	\$ 335,000,000
Pfizer, Inc.	Pfizer	kickbacks and bribery	2009	MULTI-AG	(*) \$ 331,485,170
Teva Pharmaceuticals, Ltd.	Teva Pharmaceutical Industries	off-label or unapproved promotion of medical products	2022	NY-AG	\$ 313,343,793
Johnson and Johnson	Johnson & Johnson	drug or medical equipment safety violation	2023	CA-AG	\$ 302,000,000
Bristol-Myers Squibb	Bristol-Myers Squibb	fraud	2005	USAO	\$ 300,000,000
Indivior plc	Indivior PLC	off-label or unapproved promotion of medical products	2021	MULTI-AG	\$ 300,000,000
Daiichi Sankyo Inc.	Daiichi Sankyo	product safety violation	2017	private lawsuit-federal	\$ 300,000,000
Bausch Health Companies Inc.	Bausch Health	price-fixing or anti-competitive practices	2022	private lawsuit-federal	\$ 300,000,000
Schering-Plough Corporation	Merck	kickbacks and bribery	2004	MULTI-AG	(*) \$ 292,969,482
Merck	Merck	False Claims Act and related	2008	MULTI-AG	(*) \$ 290,000,000
Pfizer	Pfizer	drug or medical equipment safety violation	2013	private lawsuit-federal	\$ 288,000,000
Mylan	Viatris	off-label or unapproved promotion of medical products	2025	MULTI-AG	\$ 284,447,916
Teva Pharmaceutical Industries Ltd	Teva Pharmaceutical Industries	Foreign Corrupt	2016	DOJ_CRIMINAL	\$ 283,177,348

COMPANY	CURRENT PARENT	PRIMARY OFFENSE TYPE	YEAR	AGENCY	PENALTY AMOUNT
		Practices Act			
Dey Inc.	Viatris	False Claims Act and related	2010	DOJ_CIVIL	\$ 280,000,000
Roxane Laboratories Inc.	Hikma Pharmaceuticals	False Claims Act and related	2010	DOJ_CIVIL	\$ 280,000,000
Celgene Corp.	Bristol-Myers Squibb	False Claims Act and related	2017	USAO	\$ 280,000,000
Teva Pharmaceutical Industries	Teva Pharmaceutical Industries	off-label or unapproved promotion of medical products	2022	FL-AG	\$ 278,826,499
Teva Pharmaceuticals USA, Inc.	Teva Pharmaceutical Industries	price-fixing or anti-competitive practices	2023	DOJ_ANTITRUST	\$ 275,000,000
Amneal Pharmaceuticals	Amneal Pharmaceuticals	off-label or unapproved promotion of medical products	2024	MULTI-AG	\$ 272,500,000
Purdue Pharma	Purdue Pharma	Controlled Substances Act violation	2019	OK-AG	\$ 270,000,000

(*): Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting.